Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2006

View Archived Issues

Clinical update on AMG-714 for RA

2-Methoxyestradiol reduces angiogenesis and signs of arthritis in animal model

Study shows potential of methotrexate/CF-101 combination in rheumatoid arthritis

Amorcyte signs development and manufacturing agreement for AMR-001

BioProgress to acquire Segix Farma

King and Depomed to copromote Glumetza

Advisory Committee review date set for Factive sNDA in acute bacterial sinusitis

Pivotal PanVac-VF study in advanced pancreatic cancer fails to meet endpoint

APEX-AMI trial of pexelizumab fails to meet primary endpoint

Prezista launched in U.S. for treatment of antiretroviral-treatment experienced patients

Japanese filing for Nexavar for renal cell carcinoma

NDA submission for AzaSite in bacterial conjunctivitis

New phase IIb study of seliciclib in previously treated NSCLC

Fast track designation for TG-100-115 for treatment of STEMI

Revised U.S. prescribing information for Ketek

Approvable letter for Fentora in breakthrough cancer pain

CK-1827452 demonstrates dose-dependent increases in indices of cardiac function

Zerenex shows utility as treatment for hyperphosphatemia in hemodialysis patients

European submission for Atriance in T-ALL and T-LBL

FDA approval for Lucentis

Astellas discontinues development of immunosuppressant FK-778

Novel mutation pattern for the protease inhibitor PL-100 identified

Novel HIV fusion inhibitors active against enfuvirtide-resistant viruses

Monoclonal antibody against the GM-CSF receptor alpha chain shows preclinical biological activity

Novel agents imparted for the treatment of arthritis and other inflammatory conditions

New treatment strategies for cancer covered in recent patents

Antipsychotic, antidepressant agents disclosed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...